Elranatamab
- Generic Name
- Elranatamab
- Brand Names
- Elrexfio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2408850-14-4
- Unique Ingredient Identifier
- L0HR9A577V
- Background
Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb, each of which contributes one heavy chain and one light chain to drug structure. The resulting 4-chain bispecific antibody is covalently linked via five inter-chain disulfide bonds. On August 14, 2023, the FDA granted accelerated approval to elranatamab for the treatment of multiple myeloma.
- Indication
Elranatamab is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).
- Associated Conditions
- Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
ASH: Blenrep ups survival by 42% in multiple myeloma trial
GSK's Blenrep showed a 42% reduced risk of death in multiple myeloma, outperforming Darzalex in the DREAMM-7 trial. With a 74% OS rate for BVd vs. 60% for DVd, and significant MRD negativity, it may redefine treatment for relapsed/refractory multiple myeloma. GSK aims for Blenrep's comeback, despite competition from newer therapies.
Peers Evaluate CAR T Referral and Bridging Process for Early Relapsed Multiple Myeloma
Experts discuss challenges in referring patients for second-line CAR T-cell therapy, especially older, frail patients, and the importance of bridging therapy. They highlight the efficacy and safety of cilta-cel in multiple myeloma, noting the need for careful patient selection and management of adverse events like CRS and ICANS.
Related Clinical Trials:
Emerging BCMA-Directed Therapies in Multiple Myeloma: Bispecific Antibodies and CAR T
Multiple myeloma (MM) is a treatable but incurable hematologic malignancy. Advances in treatment, including proteasome inhibitors and immunomodulatory agents, have improved survival rates. Current therapies focus on combination regimens, with ongoing research into bispecific antibodies and CAR T-cell therapies for relapsed/refractory MM.
Related Clinical Trials:
Advancements in Multiple Myeloma Therapies and Operational Insights in Oncology Clinical Trials
Multiple myeloma treatment advances include proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies. Bispecific antibodies (bsAbs) and CAR T-cell therapies offer new options for relapsed/refractory MM. BCMA-directed bsAbs teclistamab and elranatamab show similar efficacy, with elranatamab offering logistical advantages. CAR T-cell therapies provide high efficacy but are administered once. Optimal sequencing of bsAbs and CAR T-cell therapies is ongoing research. Operational challenges in oncology clinical trials highlight the need for targeted strategies in multi-IP trials and advanced phases.
MagnetisMM-20: Priming Myeloma Tumor Cells for the Bispecific Bout
The 66th ASH Annual Meeting featured MagnetisMM-20, a phase 1b trial evaluating elranatamab (BCMA/CD3 bispecific antibody) in combination with carfilzomib and dexamethasone for relapsed/refractory multiple myeloma. Results showed 100% unconfirmed ORR, with no dose-limiting toxicities and common AEs including fatigue and infections. The priming dose strategy worked as anticipated, and the regimen showed promise for deep and long-lasting remissions, even in high-stage patients.
GSK's multiple myeloma ADC Blenrep was pulled from the market. Now, it's poised for a comeback.
GSK's Blenrep, an antibody-drug conjugate targeting BCMA in multiple myeloma, showed a 42% reduction in death risk when combined with chemotherapy and a steroid, compared to J&J's Darzalex. Despite initial market withdrawal, GSK is optimistic about Blenrep's potential comeback, supported by new survival data and ongoing studies. The drug could face competition from emerging cell therapies and bispecific antibodies, but GSK is exploring dosing options to enhance its profile.
Dozens of Presentations Advance Multiple Myeloma Research at the American Society for ...
At the 2024 American Society of Hematology meeting, Dr. C. Ola Landgren and colleagues presented research on multiple myeloma, focusing on combination therapies, overcoming resistance, and precision medicine to improve patient outcomes and potentially cure the disease.
He Made Pfizer a Household Name. Wall Street Wants More.
Pfizer CEO Dr. Albert Bourla's bold bet on a Covid-19 vaccine paid off, making Pfizer a household name and generating billions in sales. However, Pfizer's stock price has since dropped due to miscalculated vaccine demand and underperforming post-pandemic goals. Activist investor Starboard Value has taken a $1 billion stake in Pfizer, criticizing Bourla's leadership. Despite this, Bourla enjoys support from Pfizer's board and has implemented cost-cutting measures and reorganization efforts. Pfizer's post-pandemic slump, miscalculated demand, and underperforming new drug launches have led to a significant drop in stock value. Starboard's campaign against Bourla has become personal, accusing Pfizer of pressuring former executives to support Bourla. Bourla's ambitious goals and risks during the pandemic have been both praised and criticized, with some acquisitions yet to yield results.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath